On August 25, INSILICO rose 5.5% in regular trading, trading at HKD 42.68 per share, with turnover of approximately HKD 104 million.

On the news front, the company recently announced the establishment of its first CVC (Corporate Venture Capital) industrial fund in partnership with Value Partners Shenzhen and Pufa Group, targeting a total size of RMB 1.01 billion. The fund will focus on life sciences, covering areas such as company-incubated startups, life science models, and novel drug development. Yuanma Zhiyao is expected to be among the first key projects included in the fund.

Additionally, the company is scheduled to release its interim results on August 26. The market is closely watching the recognition of major BD milestone payments within the reporting period, including the USD 115 million upfront payment from the Eli Lilly collaboration and approximately USD 60 million in initiation fees from Takeda. Earlier in July, INSILICO also announced strategic partnerships with Tencent Health and signed a tripartite cooperation agreement with Yuanma Zhiyao and Shaqiu Quantum during WAIC.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)